GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2023;402(10397):203–34.

GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204–22.

Centers for Disease Control and Prevention. National Diabetes Statistics Report website. https://www.cdc.gov/diabetes/data/statistics-report/index.html. Accessed 15 Apr 2024.

Parker ED, Lin J, Mahoney T, et al. Economic costs of diabetes in the U.S. in 2022. Diabetes Care. 2023;47(1):26–43.

Article  Google Scholar 

Fang M, Wang D, Coresh J, Selvin E. Trends in diabetes treatment and control in U.S. adults, 1999–2018. N Engl J Med. 2021;384(23):2219–28.

Article  PubMed  PubMed Central  Google Scholar 

Committee ADAPP. 8. Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of care in diabetes—2024. Diabetes Care. 2023;47(Supplement_1):S145–57.

Sattar N, Presslie C, Rutter MK, McGuire DK. Cardiovascular and kidney risks in individuals with type 2 diabetes: contemporary understanding with greater emphasis on excess adiposity. Diabetes Care. 2024;47(4):531–43.

Article  CAS  PubMed  Google Scholar 

Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753–86.

Committee ADAPP. 1. Improving care and promoting health in populations: standards of care in diabetes—2024. Diabetes Care. 2023;47(Supplement_1):S11–9.

Eli Lilly and Company. FDA approves Lilly’s Mounjaro™ (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes. https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-mounjarotm-tirzepatide-injection-first-and. Accessed 16 Apr 2024.

Eli Lilly and Company. FDA approves Lilly’s Zepbound (tirzepatide) for chronic weight management, a powerful new option for the treatment of obesity or overweight with weight-related medical problems. https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-zepboundtm-tirzepatide-chronic-weight. Accessed 16 Apr 2024.

Rosenstock J, Wysham C, Frías JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143–55.

Article  CAS  PubMed  Google Scholar 

Dahl D, Onishi Y, Norwood P, et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA. 2022;327(6):534–45.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503–15.

Article  PubMed  Google Scholar 

Ludvik B, Giorgino F, Jódar E, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021;398(10300):583–98.

Article  CAS  PubMed  Google Scholar 

Del Prato S, Kahn SE, Pavo I, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021;398(10313):1811–24.

Article  PubMed  Google Scholar 

Boye KS, Thieu VT, Sapin H, et al. Patient-reported outcomes in people with type 2 diabetes receiving tirzepatide in the SURPASS clinical trial programme. Diabetes Ther. 2023;14(11):1833–52.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402(10402):613–26.

Article  CAS  PubMed  Google Scholar 

Karakasis P, Patoulias D, Fragakis N, Klisic A, Rizzo M. Effect of tirzepatide on albuminuria levels and renal function in patients with type 2 diabetes mellitus: a systematic review and multilevel meta-analysis. Diabetes Obes Metab. 2024;26(3):1090–104.

Article  CAS  PubMed  Google Scholar 

Kamrul-Hasan ABM, Dutta D, Nagendra L, Kuchay MS, Islam MS, Pappachan JM. Hepatobiliary effects and safety of tirzepatide: a systematic review and meta-analysis. Diabetes Obes Metab. 2024;26(12):6074–9.

Article  CAS  PubMed  Google Scholar 

Popovic DS, Patoulias D, Popovic LS, Karakasis P, Papanas N, Mantzoros CS. Tirzepatide use and the risk of cancer among individuals with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Diabetes Res Clin Pract. 2024;213:111758.

Article  CAS  PubMed  Google Scholar 

Lingvay I, Mosenzon O, Brown K, et al. Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program. Cardiovasc Diabetol. 2023;22(1):66.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sattar N, McGuire DK, Pavo I, et al. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nat Med. 2022;28(3):591–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Carelon Research. 2023. Technical white paper—Carelon Research’s Healthcare Integrated Research Database (HIRD®). https://lp.carelonresearch.com/rs/621-UKX-708/images/Carelon-Research-HIRD-technical-white-paper-fv.pdf.

Stephenson JJ, Teng CC, Harris KM. Assessing the representativeness of real-world claims databases. Poster presentation at the 2024 ISPOR annual meeting, May 5–8, 2024, Atlanta, GA. https://www.ispor.org/heor-resources/presentations-database/presentation/intl2024-3897/139401. Accessed 18 June 2024.

U.S. Census Bureau. American Community Survey 5-year data profile. In: Hillcrest Heights, MD.

Food Access Research Atlas. https://www.ers.usda.gov/data-products/food-access-research-atlas/about-the-atlas/. Accessed 16 Apr 2024.

National Center for Health Statistics. https://www.cdc.gov/nchs/data_access/urban_rural.htm. Accessed 16 Apr 2024.

Frazer M, Swift C, Sargent A, et al. Real-world HbA1c changes and prescription characteristics among type 2 diabetes mellitus patients initiating treatment with once weekly semaglutide for diabetes. J Diabetes Metab Disord. 2023;23(1):727–37

Williams DM, Ruslan AM, Khan R, et al. Real-world clinical experience of semaglutide in secondary care diabetes: a retrospective observational study. Diabetes Ther. 2021;12(3):801–11.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Visaria J, Uzoigwe C, Swift C, Dang-Tan T, Paprocki Y, Willey VJ. Real-world effectiveness of once-weekly semaglutide from a US commercially insured and medicare advantage population. Clin Ther. 2021;43(5):808–21.

Article  CAS  PubMed  Google Scholar 

Mody R, Yu M, Grabner M, Boye K, Teng C-C, Kwan AYM. Dulaglutide shows sustained reduction in glycosylated hemoglobin values: 2-year US real-world study results. Clin Ther. 2020;42(11):2184–95.

Article  CAS  PubMed  Google Scholar 

Mody R, Grabner M, Yu M, et al. Real-world effectiveness, adherence and persistence among patients with type 2 diabetes mellitus initiating dulaglutide treatment. Curr Med Res Opin. 2018;34(6):995–1003.

Article  CAS  PubMed  Google Scholar 

Falconi AM, Johnson M, Chi W, Stephenson JJ, Marc Overhage J, Agrawal S. Health related social needs and whole person health: relationship between unmet social needs, health outcomes, and healthcare spending among commercially insured adults. Prev Med Rep. 2023;36:102491.

Article  PubMed  PubMed Central  Google Scholar 

Hill-Briggs F, Adler NE, Berkowitz SA, et al. Social determinants of health and diabetes: a scientific review. Diabetes Care. 2020;44(1):258–79.

Article  PubMed  PubMed Central  Google Scholar 

Ryan JL, Franklin SM, Canterberry M, et al. Association of health-related social needs with quality and utilization outcomes in a medicare advantage population with diabetes. JAMA Netw Open. 2023;6(4):e239316.

Article  PubMed  PubMed Central  Google Scholar 

Walker RJ, Gebregziabher M, Martin-Harris B, Egede LE. Quantifying direct effects of social determinants of health on glycemic control in adults with type 2 diabetes. Diabetes Technol Ther. 2015;17(2):80–7.

Article  PubMed  PubMed Central  Google Scholar 

Chang R, Philip J, Javed U, et al. Unfavorable social determinants of health and risk of mortality in adults with diabetes: findings from the National Health Interview Survey. BMJ Open Diabetes Res Care. 2024;12(1):e003710.

Volaco A, Cavalcanti AM, Filho RP, Précoma DB. Socioeconomic status: the missing link between obesity and diabetes mellitus? Curr Diabetes Rev. 2018;14(4):321–6.

Article  PubMed  Google Scholar 

Kirkman MS, Rowan-Martin MT, Levin R, et al. Determinants of adherence to diabetes medications: findings from a large pharmacy claims database. Diabetes Care. 2015;38(4):604–9.

Article  PubMed  PubMed Central  Google Scholar 

Silva-Tinoco R, Cuatecontzi-Xochitiotzi T, De la Torre-Saldaña V, et al. Influence of social determinants, diabetes knowledge, health behaviors, and glycemic control in type 2 diabetes: an analysis from real-world evidence. BMC Endocr Disord. 2020;20(1):130.

Article  CAS  PubMed  PubMed Central